IPP Bureau

Panacea Biotec to manufacture 10 crore doses per year of Sputnik V
Panacea Biotec to manufacture 10 crore doses per year of Sputnik V

By IPP Bureau - May 24, 2021

First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer

Five manufacturers get license to produce Black Fungus drug
Five manufacturers get license to produce Black Fungus drug

By IPP Bureau - May 23, 2021

NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers

Orchid Pharma Q4FY21 consolidated loss at Rs. 24.72 Cr
Orchid Pharma Q4FY21 consolidated loss at Rs. 24.72 Cr

By IPP Bureau - May 23, 2021

The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021

Bharat Parenterals receives license for Favipiravir Oral Suspension
Bharat Parenterals receives license for Favipiravir Oral Suspension

By IPP Bureau - May 23, 2021

The product patent has been already filed under fast track approval

Orchid Pharma develops new molecule OCID-5090
Orchid Pharma develops new molecule OCID-5090

By IPP Bureau - May 23, 2021

Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.

Balaxi records Q4 FY21 revenue of Rs. 53 Cr
Balaxi records Q4 FY21 revenue of Rs. 53 Cr

By IPP Bureau - May 22, 2021

Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday

Govt. monitoring supply of COVID-19 essential drugs
Govt. monitoring supply of COVID-19 essential drugs

By IPP Bureau - May 21, 2021

Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.

Cipla launches Covid-19 RT-PCR test Viragen
Cipla launches Covid-19 RT-PCR test Viragen

By IPP Bureau - May 21, 2021

This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19

India's first indigenous COVID-19 RT-PCR testing kit approved
India's first indigenous COVID-19 RT-PCR testing kit approved

By IPP Bureau - May 21, 2021

This kit was developed in partnership with Gujarat-based LabCare Diagnostics. LabCare is into clinical chemistry reagents, serology tests, immuno-chromatographic tests and urine analysis strips

Dishman Carbogen Amcis announces successful results for treatment for vitamin D deficiency
Dishman Carbogen Amcis announces successful results for treatment for vitamin D deficiency

By IPP Bureau - May 21, 2021

Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.

Remdesivir production increased to 119 lakh vials per month
Remdesivir production increased to 119 lakh vials per month

By IPP Bureau - May 18, 2021

Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60

Sun Pharma Advanced Research Q4FY21 loss at Rs. 56.72 Cr
Sun Pharma Advanced Research Q4FY21 loss at Rs. 56.72 Cr

By IPP Bureau - May 18, 2021

The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020

NATCO signs licensing agreement with Lilly for Baricitinib
NATCO signs licensing agreement with Lilly for Baricitinib

By IPP Bureau - May 18, 2021

Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India

Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine
Shilpa Medicare to produce 50 mn doses of Sputnik V Vaccine

By IPP Bureau - May 18, 2021

Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production

Outlook promising for Cipla: HDFC Securities
Outlook promising for Cipla: HDFC Securities

By IPP Bureau - May 18, 2021

The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.

Latest Stories

Interviews

Packaging